DND Technologies, Inc. (DNDT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DND Technologies, Inc. (DNDT) trades at $0.06 with AI Score 44/100 (Grade C). DND Technologies, Inc. operates as a holding company, producing and distributing specialty balms and pharmaceutical products. Market cap: $184,262, Sector: Consumer defensive.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for DNDT: DNDT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DNDT against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DNDT: the 1 perspectives are evenly split.
How is this calculated? →DND Technologies, Inc. (DNDT) Consumer Business Overview
DND Technologies, Inc., established in 1997, focuses on specialty balms and pharmaceutical products, including its Bioassaygen line, distributed via wholesale, retail, and online channels. Operating within the consumer defensive sector, the company faces challenges typical of OTC-listed entities with negative profitability and shell risk concerns.
What Is the Investment Thesis for DNDT?
Investing in DND Technologies, Inc. (DNDT) presents significant risks due to its OTC listing and negative profitability, as reflected by its P/E ratio of -38.06. The company's product line, centered around the Bioassaygen series, targets the skincare market, but its ability to compete effectively is uncertain. Growth catalysts would depend on successful product development and market penetration, but the company's financial health raises concerns about its long-term viability. The negative beta of -4.27 suggests an inverse correlation with the market, which could be a defensive characteristic in certain market conditions, but also indicates potential instability. Investors should carefully assess the risks associated with OTC-listed companies, including limited liquidity and disclosure.
Based on FMP financials and quantitative analysis
DNDT Key Highlights
- Market capitalization of 184K indicates a very small company size.
- Negative P/E ratio of -38.06 reflects current unprofitability.
- Beta of -4.27 suggests an inverse correlation with market movements.
- Operates in the Consumer Defensive sector, which is generally stable but may offer limited growth potential.
- Distribution strategy includes wholesale, retail, and internet channels, providing market access.
Who Are DNDT's Competitors?
DNDT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHA Chagee Holdings Limited American Depositary Shares | $11.19 | +1.59% | $2.13B | 66 |
| PRMB Primo Brands Corporation | $24.89 | -0.52% | $9.03B | 59 |
| BNKK Bonk, Inc. | $1.49 | +2.76% | $8.18M | 58 |
| HAATF Haad Thip Public Company Limited | $0.48 | +0.00% | $194.45M | 57 |
| OSHIF Oishi Group PLC | $1.24 | +0.00% | 46 | |
| REED Reed's, Inc. | $1.27 | -4.51% | $11.89M | 46 |
| UPCHY Uni-President China Holdings Ltd | $97.67 | +12.91% | $42.19M | 46 |
| FQVTF Fevertree Drinks PLC | $10.40 | -4.46% | $1.18B | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DNDT's Key Strengths?
- Proprietary Bioassaygen product line.
- Multi-channel distribution network.
- Focus on specialty skincare products.
- Established presence since 1997.
What Are DNDT's Weaknesses?
- Negative profitability (P/E ratio of -38.06).
- OTC listing indicates higher risk.
- Limited market capitalization ($0.00B).
- Potential shell risk.
What Could Drive DNDT Stock Higher?
- Potential development of new Bioassaygen product lines to address evolving consumer needs.
- Expansion of online sales channels to reach a broader customer base.
- Strategic partnerships with retailers to increase product visibility and distribution.
- Potential for international expansion into new markets.
- Targeted marketing campaigns to drive brand awareness and sales.
What Are the Key Risks for DNDT?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition in the skincare market could erode market share.
- Changing consumer preferences may require significant product innovation.
- Regulatory challenges for pharmaceutical products could increase compliance costs.
- Economic downturns affecting consumer spending could reduce sales.
- OTC listing carries inherent risks of limited disclosure and liquidity.
What Are the Growth Opportunities for DNDT?
- Expansion of Online Sales Channels: DND Technologies can capitalize on the growing e-commerce trend by expanding its online sales channels. The global e-commerce market is projected to reach trillions of dollars in the coming years, offering a significant opportunity for DND Technologies to increase its market reach and sales volume. Investing in a user-friendly website and targeted digital marketing campaigns could attract a wider customer base and drive revenue growth. Timeline: Within the next 2-3 years.
- Development of New Product Lines: DND Technologies can diversify its product portfolio by developing new product lines that cater to evolving consumer preferences. The skincare market is constantly evolving, with new ingredients and technologies emerging regularly. Investing in research and development to create innovative products could attract new customers and increase brand loyalty. Timeline: Ongoing.
- Strategic Partnerships with Retailers: DND Technologies can expand its distribution network by forming strategic partnerships with major retailers. Securing shelf space in established retail chains would provide greater visibility and accessibility to consumers. Negotiating favorable terms and providing attractive incentives could encourage retailers to carry DND Technologies' products. Timeline: Within the next 1-2 years.
- Targeted Marketing Campaigns: DND Technologies can implement targeted marketing campaigns to reach specific customer segments. By identifying the demographics and preferences of its target audience, the company can tailor its marketing messages and channels to maximize impact. Utilizing social media, influencer marketing, and search engine optimization could increase brand awareness and drive sales. Timeline: Ongoing.
- International Expansion: DND Technologies can explore opportunities for international expansion to tap into new markets. The global skincare market is vast, with significant growth potential in emerging economies. Conducting market research to identify promising regions and adapting its products and marketing strategies to local preferences could drive revenue growth. Timeline: Within the next 3-5 years.
What Opportunities Does DNDT Have?
- Expansion of online sales channels.
- Development of new product lines.
- Strategic partnerships with retailers.
- International expansion.
What Threats Does DNDT Face?
- Intense competition in the skincare market.
- Changing consumer preferences.
- Regulatory challenges for pharmaceutical products.
- Economic downturns affecting consumer spending.
What Are DNDT's Competitive Advantages?
- Proprietary formulations for Bioassaygen products.
- Established distribution network through multiple channels.
- Focus on niche market segments within the skincare industry.
- Brand recognition, if established, for Bioassaygen products.
What Does DNDT Do?
Founded in 1997 and based in New York City, DND Technologies, Inc. functions as a holding company engaged in the production and distribution of specialty balms and pharmaceutical products. The company's core product line centers around its Bioassaygen series, which includes Bioassaygen Gel, designed to reduce wrinkles and promote skin regeneration; Bioassaygen Cosmetic Mask for cosmetic applications; Bioassaygen Bio-Skin, a skin replacement bandage; and Bioassaygen Delivery Gel, intended to accelerate skin regeneration. These products are distributed through a multi-channel approach, encompassing wholesale, retail outlets, and online sales platforms. DND Technologies aims to serve a market interested in specialty skincare and pharmaceutical solutions. However, its current market capitalization is negligible, and it operates with a negative price-to-earnings ratio, indicating unprofitability. As an OTC-listed company, DND Technologies faces unique regulatory and financial scrutiny.
What Products and Services Does DNDT Offer?
- Produces specialty balms for various applications.
- Manufactures pharmaceutical products, including skincare gels and masks.
- Develops skin replacement bandages under the Bioassaygen brand.
- Distributes products through wholesale channels.
- Sells products through retail outlets.
- Offers products for sale via the Internet.
How Does DNDT Make Money?
- Develops and manufactures specialty balms and pharmaceutical products.
- Distributes products through wholesale, retail, and online channels.
- Generates revenue through product sales.
- Focuses on skincare and skin regeneration products.
What Industry Does DNDT Operate In?
DND Technologies, Inc. operates within the consumer defensive sector, specifically in the non-alcoholic beverages and specialty pharmaceutical sub-segments. This sector is characterized by relatively stable demand, as consumers tend to maintain their spending on essential goods and services even during economic downturns. However, the market is highly competitive, with established players like AJOY, ASII, DNAX, FHBC, and HFBG dominating market share. DND Technologies faces the challenge of differentiating its products and establishing a strong brand presence in a crowded market. The company's focus on specialty balms and skincare products positions it within a niche market, but success depends on effective marketing and distribution strategies.
Who Are DNDT's Key Customers?
- Individuals seeking skincare solutions.
- Consumers interested in anti-aging products.
- Patients requiring skin replacement bandages.
- Wholesale distributors.
- Retail partners.
DND Technologies, Inc. (DNDT) Valuation Context
Valued at 184K, DNDT is classified as a micro-cap stock. Relative to its peer group, DNDT's quantitative score of 44/100 is below the peer average of 57/100.
ROE 2%Key Financial Metrics
Return on equity for DND Technologies, Inc. stands at 2.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
DND Technologies, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
DNDT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary Bioassaygen product line.
- Multi-channel distribution network.
- Focus on specialty skincare products.
- Established presence since 1997.
Bear Case
- Negative profitability (P/E ratio of -38.06).
- OTC listing indicates higher risk.
- Limited market capitalization ($0.00B).
- Potential shell risk.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
DNDT Latest News
No recent news available for DNDT.
DNDT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DNDT.
Price Targets
Wall Street price target analysis for DNDT.
DNDT MoonshotScore
What does this score mean?
The MoonshotScore rates DNDT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Hong
CEO
David Hong serves as the Chief Executive Officer of DND Technologies, Inc. His background includes experience in the pharmaceutical and consumer goods sectors. He has held various leadership positions in companies focused on product development and distribution. His expertise lies in strategic planning, market analysis, and operational management. He is responsible for guiding DND Technologies' overall strategy and ensuring its long-term growth and profitability. He is a graduate of a leading business school.
Track Record: Under David Hong's leadership, DND Technologies has focused on expanding its product line and distribution channels. He has overseen the development of new Bioassaygen products and the implementation of targeted marketing campaigns. Key milestones include establishing partnerships with retailers and expanding the company's online presence. However, the company's financial performance remains a challenge, with ongoing efforts to improve profitability.
DNDT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that DND Technologies, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. The presence of shell risk further compounds these concerns.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low liquidity and high bid-ask spreads.
- Potential for fraud or manipulation.
- Shell risk detected.
- Limited regulatory oversight.
- Verify the company's legal status and registration.
- Investigate the background and experience of the management team.
- Attempt to obtain audited financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and debt levels.
- Understand the risks associated with OTC investing.
- Consult with a financial advisor before investing.
- Years in operation since 1997.
- Presence of a CEO (David Hong).
- Product offerings in the market.
- Multi-channel distribution strategy.
DNDT Consumer Defensive Stock FAQ
What does DND Technologies, Inc. do?
DND Technologies, Inc. operates as a holding company that produces and distributes specialty balms and pharmaceutical products, primarily under the Bioassaygen brand. Their product line includes gels, masks, and skin replacement bandages designed for skincare and skin regeneration. The company distributes its products through wholesale, retail outlets, and online sales channels, targeting consumers interested in specialty skincare solutions. However, its OTC listing and negative profitability raise concerns about its long-term financial viability and market competitiveness.
What do analysts say about DNDT stock?
As of 2026-03-18, there is no readily available analyst coverage for DNDT stock due to its OTC listing and limited market capitalization. Key valuation metrics, such as price-to-earnings ratio, are negative, reflecting current unprofitability. Growth considerations depend on successful product development, market penetration, and improved financial performance. Investors should conduct thorough due diligence and carefully assess the risks associated with OTC-listed companies before considering an investment in DNDT.
What are the main risks for DNDT?
The main risks for DNDT include its OTC listing, which entails limited financial disclosure, low liquidity, and potential for fraud or manipulation. The company's negative profitability and small market capitalization also pose significant challenges. Additionally, DNDT faces intense competition in the skincare market, changing consumer preferences, and regulatory challenges for pharmaceutical products. The detected shell risk further compounds these concerns, requiring investors to exercise extreme caution and conduct thorough due diligence.
What are the key factors to evaluate for DNDT?
DND Technologies, Inc. (DNDT) holds an AI score of 44/100 (low). Not financial advice.
How frequently does DNDT data refresh on this page?
DNDT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DNDT's recent stock price performance?
DND Technologies, Inc. (DNDT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Bioassaygen product line. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DNDT overvalued or undervalued right now?
Valuing DND Technologies, Inc. (DNDT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DNDT?
Before investing in DND Technologies, Inc. (DNDT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing and lack of analyst coverage.
- Financial data is based on available information and may not be comprehensive.
- AI analysis pending for DNDT.